Trial Profile
An Open-Label Prospective, Randomized, Multicenter Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Basiliximab
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 13 May 2009 New trial record.